- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 247649, 7 pages
What Is the Role of Apelin regarding Cardiovascular Risk and Progression of Renal Disease in Type 2 Diabetic Patients with Diabetic Nephropathy?
1Nephrology Department, Hospital Faro, Rua Leão Penedo, 8000-386 Faro, Portugal
2Pathology Clinic, Hospital Faro, 8000-836 Faro, Portugal
3Science of the Sea Department, University of Algarve, 8000-140 Faro, Portugal
4Cardiology Department, Hospital Faro, 8000-386 Faro, Portugal
5Pharmacology Department, Gnostic Laboratory, 8000-307 Faro, Portugal
Received 30 April 2013; Revised 5 August 2013; Accepted 8 August 2013
Academic Editor: Denis Feliers
Copyright © 2013 Ana Paula Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. Walatek and W. Sulowicz, “Cardiorenal syndrome–alternate challenge for nephrologist,” Przeglad Lekarski, vol. 68, no. 9, pp. 619–628, 2011.
- J. Malyszko, J. S. Malyszko, K. Pawlak, and M. Mysliwiec, “Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure,” Advances in Medical Sciences, vol. 53, pp. 32–36, 2008.
- R. S. Ahima, “Metabolic actions of adipocyte hormones: focus on adiponectin,” Obesity, vol. 14, no. 2, pp. 9–15, 2006.
- P. Kougias, H. Chai, P. H. Lin, Q. Yao, A. B. Lumsden, and C. Chen, “Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease,” Journal of Surgical Research, vol. 126, no. 1, pp. 121–129, 2005.
- J. Małyszko, J. S. Małyszko, P. Koźminski, and M. Myśliwiec, “Apelin and cardiac function in hemodialyzed patients: possible relations?” American Journal of Nephrology, vol. 26, no. 2, pp. 121–126, 2006.
- K. Tatemoto, M. Hosoya, Y. Habata et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998.
- C. J. Charles, “Putative role for apelin in pressure/volume homeostasis and cardiovascular disease,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 5, no. 1, pp. 1–10, 2007.
- B. Chandrasekaran, O. Dar, and T. McDonagh, “The role of apelin in cardiovascular function and heart failure,” European Journal of Heart Failure, vol. 10, no. 8, pp. 725–732, 2008.
- American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, Supplement 1, pp. S62–S69, 2010.
- D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
- A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999.
- A. M. El-Shehaby, M. M. El-Khatib, A. A. Battah, and A. R. Roshdy, “Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 6, pp. 421–427, 2010.
- V. O. Leal, J. C. Lobo, M. B. Stockler-Pinto, et al., “Apelin: a peptide involved in cardiovascular risk in hemodialysis patients?” Renal Failure, vol. 34, no. 5, pp. 577–581, 2012.